HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma.

AbstractOBJECTIVE:
To evaluate the impact of adjuvant post-operative therapy in women with early stage uterine carcinosarcoma.
METHODS:
After IRB approval was obtained at all sites, a multi-center retrospective study of women with FIGO stage I-II uterine carcinosarcoma diagnosed from 1997 to 2007 was conducted. Post-operative treatment included observation (OBS), radiation (RT), chemotherapy (CT) alone or with RT (CT+RT). Data analyzed included demographic and pathologic factors, adjuvant therapy outcomes, and time-to-event information. The Kaplan-Meier method was used to estimate time-to-event functions. Cox regression modeling was used to examine the impact of selected covariates on progression free survival (PFS), and overall survival (OS).
RESULTS:
111 women were identified: 94 (85%) had stage I and 17 (15%) had stage II uterine carcinosarcoma. Forty-four women (40%) did not receive adjuvant therapy (OBS), 29 (26%) women had adjuvant CT, 23 (20%) women underwent RT and 15 (14%) women underwent RT+CT. Seventy-three patients were alive without disease and 38 had progressed or died at the close of data collection. In multivariate analysis, CT (p=0.003), LVSI (p<0.0001) and a pre-existing cancer (p=0.004) were most predictive of PFS. LVSI was predictive of shortened OS (p=0.01).
CONCLUSIONS:
In women with FIGO stage I-II uterine carcinosarcoma, adjuvant chemotherapy is associated with improved PFS compared to radiation or observation alone. Ongoing clinical trials will clarify the role of chemotherapy in women with this disease.
AuthorsLeigh A Cantrell, Laura Havrilesky, Dominic T Moore, David O'Malley, Margaret Liotta, Angeles Alvarez Secord, Christa I Nagel, David E Cohn, Amanda Nickles Fader, Amy H Wallace, Peter Rose, Paola A Gehrig
JournalGynecologic oncology (Gynecol Oncol) Vol. 127 Issue 1 Pg. 22-6 (Oct 2012) ISSN: 1095-6859 [Electronic] United States
PMID22727985 (Publication Type: Journal Article, Multicenter Study)
CopyrightCopyright © 2012. Published by Elsevier Inc.
Topics
  • Aged
  • Aged, 80 and over
  • Carcinosarcoma (drug therapy, pathology, radiotherapy, surgery)
  • Chemoradiotherapy, Adjuvant
  • Chemotherapy, Adjuvant
  • Cohort Studies
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Staging
  • Radiotherapy, Adjuvant
  • Retrospective Studies
  • Risk Factors
  • Survival Analysis
  • Uterine Neoplasms (drug therapy, pathology, radiotherapy, surgery)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: